G2-S16 dendrimer microbicide does not interfere with the vaginal immune system

Journal of Nanobiotechnology

Ana Judith Perisé-Barrios¹  Daniel Sepúlveda-Crespo¹  Mª Angeles Muñoz-Fernández²  Alba Martín-Moreno²  Mª Jesús Serramía-Lobera² 

[1] 0000 0001 0277 7938, grid.410526.4, Sección Inmunología, Laboratorio InmunoBiología Molecular, Hospital General Universitario Gregorio Marañón (HGUGM), Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), and Spanish HIV-HGM BioBank, Madrid, Spain;0000 0001 0277 7938, grid.410526.4, Sección Inmunología, Laboratorio InmunoBiología Molecular, Hospital General Universitario Gregorio Marañón (HGUGM), Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), and Spanish HIV-HGM BioBank, Madrid, Spain;Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Madrid, Spain;

关键词: G2-S16 dendrimer;    Microbicide;    Immunity;    Antigen presenting cells;    Lymphocytes;   

DOI  :  10.1186/s12951-019-0496-9

来源: publisher

【 摘 要 】

It is essential that prophylactic drugs do not interfere with the normal function of the immune system. The use of nanoparticles as vaginal microbicides is a promising prevention strategy against sexually transmitted infections. With that aim, our group is working with the G2-S16, a second generation carbosilane dendrimer with sulfonate groups in the periphery, which has been previously shown to be effective against HIV-1 and HSV-2 infection, and it is now on the road to clinical trials. Our objective in this new study is to assess the effects of G2-S16 on the immune barrier of the female reproductive tract. The expression of differentiation, maturation and activation markers was measured in epithelial cells, dendritic cells, M and GM macrophages, and T cells using RT-qPCR and flow cytometry. The results demonstrate that G2-S16 does not alter the natural immunity of the vagina, strongly supporting the biosafety of this dendrimer for clinical use.

【 授权许可】

CC BY